{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.33","upperLimit":"31.56","value":"29.94"},{"groupId":"OG001","lowerLimit":"20.16","upperLimit":"23.31","value":"21.74"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.38","upperLimit":"8.33","value":"7.35"},{"groupId":"OG001","lowerLimit":"2.51","upperLimit":"4.41","value":"3.46"}]}],"title":"Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.10","upperLimit":"23.52","value":"21.81"},{"groupId":"OG001","lowerLimit":"14.96","upperLimit":"18.30","value":"16.63"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.38","upperLimit":"16.57","value":"14.97"},{"groupId":"OG001","lowerLimit":"10.33","upperLimit":"13.45","value":"11.89"}]}],"title":"Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.26","upperLimit":"24.19","value":"22.22"},{"groupId":"OG001","lowerLimit":"18.81","upperLimit":"22.65","value":"20.73"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.12","upperLimit":"16.21","value":"14.66"},{"groupId":"OG001","lowerLimit":"3.11","upperLimit":"6.13","value":"4.62"}]}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.66","upperLimit":"12.82","value":"11.24"},{"groupId":"OG001","lowerLimit":"8.29","upperLimit":"11.37","value":"9.83"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.54","upperLimit":"20.95","value":"19.25"},{"groupId":"OG001","lowerLimit":"5.59","upperLimit":"8.91","value":"7.25"}]}],"title":"Diarrhoea"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.42","upperLimit":"16.82","value":"15.12"},{"groupId":"OG001","lowerLimit":"12.26","upperLimit":"15.59","value":"13.92"}]}],"title":"Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"PROs assessed health-related QoL by using the EORTC QLQ-C30, which was a 30 multi-item symptom scales (fatigue, nausea/vomiting, \\& pain), and 6 single item symptom scales for other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, \\& the financial impact of cancer). The questionnaire includes 28 items with 4-point Likert type responses from \"not at all\" to \"very much\" to assess symptoms. All responses were converted to a 0 to 100 scale using a standard scoring algorithm, higher scores represented more severe symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1); subsequent cycles (Day 1) and end of treatment/withdrawal (ie, up to 1 year)","title":"PROs- EORTC QLQ-C30: Symptom Scale Scores Between Treatment Comparison","type":"SECONDARY","unitOfMeasure":"Scores on scale"}